Online inquiry

IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15845MR)

This product GTTS-WQ15845MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&SSTR2 gene. The antibody can be applied in Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001050.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 6752
UniProt ID P07766; P30874
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15845MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12853MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ1863MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ8855MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ12321MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ13856MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ4338MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ8206MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ5377MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW